The treatments are Sivextro (tedizolid phosphate), from Cubist Pharmaceuticals, and Dalvance (vancomycin-linezolid combination), from Durata Therapeutics. Sivextro is a daily oral or intravenous drug, while Dalvance is a weekly IV treatment.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Both drugs successfully completed phase III clinical trials to be considered for approval, according to a Medscape report. However, the drugs will be subject to postmarket safety monitoring, as concerns raised during public hearings included a lack of diversity in the study populations and use of drug-to-drug efficacy comparisons instead of drug-to-disease efficacy comparisons.
More Articles on Infection Control & Clinical Quality:
Lucrative Treatments Overlooked for Lists of Unnecessary Procedures
Direct Patient Education Improves Adherence to Drug-Use Guidelines
3 Tips to Prevent Cardiac SSIs From Cleveland Clinic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
